Impel NeuroPharma

OverviewSuggest Edit

Impel NeuroPharma is a Seattle-based company developing intranasal drug treatments for central nervous system (CNS) disorders. Impel has developed a novel drug delivery platform, the POD technology, that administers drug to the deep nasal cavity to improve the brain distribution of many drugs. Impel’s proprietary (POD) device technology enables entirely new categories of drugs, including biologics, to be delivered to the central nervous system using a cost-effective, disposable, non-invasive intranasal drug delivery device.

The goal at Impel is simple: we want to develop the next generation of therapeutics for central nervous system (CNS) disorders. Patients with CNS disorders are vastly underserved by current therapeutics and we are working hard to change that. Impel has built the POD drug delivery platform to allow entire classes of molecules to reach the brain that never could before. Impel has expanded its scope to both partnership with pharmaceutical companies and the development of our own drug products compatible with the POD platform. We take a comprehensive approach to development and design considering patient comfort, regulatory approval pathways, and cost effectiveness. Treatments currently under development include therapies for migraine, Alzheimer’s disease, Parkinson’s disease, and pain relief

TypePrivate
Founded2008
HQSeattle, US
Websiteimpelnp.com
Employee Ratings4.1

Latest Updates

Employees (est.) (Nov 2020)67(-1%)
Cybersecurity ratingAMore

Key People/Management at Impel NeuroPharma

John Hoekman

John Hoekman

Co-Founder, CSO and Director
Adrian Adams

Adrian Adams

Chairman & CEO
Diane Wilfong

Diane Wilfong

Director
H. Stewart Parker

H. Stewart Parker

Director
John Leaman

John Leaman

Chief Financial Officer
Timothy S. Nelson

Timothy S. Nelson

Director
Show more

Impel NeuroPharma Office Locations

Impel NeuroPharma has an office in Seattle
Seattle, US (HQ)
Waterfront Research Center, 201 Elliott Ave W #260
Show all (1)

Impel NeuroPharma Financials and Metrics

Summary Metrics

Founding Date

2008

Impel NeuroPharma total Funding

$108.1 m

Impel NeuroPharma latest funding size

$67.50 m

Time since last funding

2 years ago

Impel NeuroPharma investors

Impel NeuroPharma's latest funding round in December 2018 was reported to be $67.5 m. In total, Impel NeuroPharma has raised $108.1 m
Show all financial metrics

Impel NeuroPharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Impel NeuroPharma Online and Social Media Presence

Embed Graph

Impel NeuroPharma News and Updates

Impel NeuroPharma Presents Data From INP104 Clinical Program In Acute Migraine At The 2020 American Headache Society (AHS) Virtual Annual Scientific Meeting

SEATTLE, June 15, 2020 /PRNewswire/ -- Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced that...

Impel NeuroPharma to Present Data From INP104 Clinical Program at the 61st Annual Scientific Meeting of the American Headache Society

SEATTLE, July 10, 2019 /PRNewswire/ -- Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announcedthat...

Impel Neuropharma to Present Data at 2019 American Psychiatric Association (APA) Annual Meeting

SEATTLE, May 17, 2019 /PRNewswire/ -- Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies that unlock the full potential of proven medicines for patients living with central nervous system (CNS) disorders...

Impel NeuroPharma To Present Data Highlighting Late-Stage Central Nervous System Pipeline At 2019 American Academy Of Neurology Meeting

SEATTLE, April 30, 2019 /PRNewswire/ -- Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapeutics for patients suffering from central nervous system (CNS) disorders with high unmet medical needs, today...

Impel Neuropharma Announces Positive Phase 1 Trial For INP105 For The Treatment Of Acute Agitation In Bipolar I Disorder And Schizophrenia

SEATTLE, Jan. 6, 2019 /PRNewswire/ -- Impel NeuroPharma, a Seattle-based, privately-held biopharmaceutical company focused on innovative therapies for the treatment of central nervous system (CNS) disorders, today announced positive results of a Phase 1 trial of INP105. INP105 is a...

Impel NeuroPharma Closes $67.5 Million Series D Financing

SEATTLE, Dec. 6, 2018 /PRNewswire/ -- Impel NeuroPharma ("Impel" or the "Company"), a Seattle-based, privately-held biotechnology company focused on developing therapies for the treatment of central nervous system ("CNS") disorders with unmet medical needs, today announced that it has...

Impel NeuroPharma Blogs

IMPEL NEUROPHARMA ANNOUNCES FDA SUBMISSION OF NEW DRUG APPLICATION FOR INP104 FOR THE ACUTE TREATMENT OF MIGRAINE

~The INP104 New Drug Application is Supported by Results from the Phase 3 STOP 301 Study~ ~Dihydroergotamine mesylate (DHE) is Administered via Impel’s Proprietary Precision Olfactory Delivery (POD®) Technology, the First and Only Delivery System to Utilize the Vascular-Rich Upper Nasal Space as a P…

IMPEL NEUROPHARMA PRESENTS DATA FROM PIVOTAL PHASE 3 REGISTRATION STUDY OF INP104 FOR THE TREATMENT OF ACUTE MIGRAINE AT 2020 MIGRAINE TRUST VIRTUAL SYMPOSIUM

66.3% of Patients Reported Pain Relief Within Two Hours of Treatment with Rapid Uptake via the Upper Nasal Space Resulting in Onset of Relief as Early as 15 Minutes for Some Patients Data Suggest Use of Impel’s Proprietary Precision Olfactory Delivery (POD®) Technology with DHE May Offer Convenience…

When Pills Do Not Work : Gastroparesis In Migraine

Presented at the 2020 Migraine Trust International Symposium Authors: Sheena Aurora, Linda Nguyen, Sutapa Ray, Stephen Shrewsbury Introduction: An understanding of gastric dysmotility is important to patients and physicians since it has implications in treatment of migraine. Objectives: Gastric stas…

A LONG TERM, OPEN LABEL STUDY OF SAFETY AND TOLERABILITY OF PRECISION OLFACTORY DELIVERY OF DHE IN ACUTE MIGRAINE (STOP 301): CLINICAL RESULTS

Selected as a live presentation at the 2020 Migraine Trust International Symposium Authors: Sheena Aurora, Maria Jeleva, Jasna Hocevar-Trnka, John Hoekman, Stephen Shrewsbury Introduction: Migraine is a common neurological disease impacting at least 12% of the US population. Despite several recent a…

A long term, open label study of Safety and Tolerability Of Precision olfactory delivery of DHE in acute migraine (STOP 301): Clinical Results

Presented at the 2020 PAINWeek Live Virtual Conference Authors: Sheena Aurora, Maria Jeleva, Jasna Hocevar-Trnka, John Hoekman, Stephen Shrewsbury Introduction: Migraine is a common neurological disease impacting at least12% of the United States population. Despite several recent approvals of novel …

Patient Acceptability of a Novel Upper Nasal Delivery System for DHE – Using the Precision Olfactory Delivery (POD®) Device (INP104)

Presented at the 2020 PAINWeek Live Virtual Conference Authors: Stephen B. Shrewsbury, Sheena K. Aurora, John Hoekman, Maria Jeleva Introduction: DHE is an effective acute treatment for episodic migraine, but from 1946–1996 was only available as an injection. Nasal DHE (Migranal ® ) introduced in 19…
Show more

Impel NeuroPharma Frequently Asked Questions

  • When was Impel NeuroPharma founded?

    Impel NeuroPharma was founded in 2008.

  • Who are Impel NeuroPharma key executives?

    Impel NeuroPharma's key executives are John Hoekman, Adrian Adams and Diane Wilfong.

  • How many employees does Impel NeuroPharma have?

    Impel NeuroPharma has 67 employees.

  • Who are Impel NeuroPharma competitors?

    Competitors of Impel NeuroPharma include Allurion Technologies, Spine Wave and Acessa (Halt Medical).

  • Where is Impel NeuroPharma headquarters?

    Impel NeuroPharma headquarters is located at Waterfront Research Center, 201 Elliott Ave W #260, Seattle.

  • Where are Impel NeuroPharma offices?

    Impel NeuroPharma has an office in Seattle.

  • How many offices does Impel NeuroPharma have?

    Impel NeuroPharma has 1 office.